What Solpadeine Max (+Caffeine) treats: main uses and benefits

This combination analgesic is commonly used when the intensity of pain is moderate and standard, single-ingredient pain relievers are not providing adequate relief. This therapeutic category is considered relevant for managing symptoms that interfere with daily comfort. The formulation supports symptomatic management for acute episodes of pronounced symptomatic discomfort across several key domains, including headache and migraine, sharp dental pain (toothache), intense period pain, backache, and pain related to minor strains and sprains.

---

This support assists with maintaining functional stability during periods of heightened symptoms. The medication is relevant for easing symptoms related to systemic imbalance, where it is commonly used to help with reducing high temperature (fever) and generalized body aches and pains associated with cold and flu.

“This medicine is applied across domains where additional symptomatic support is needed, contributing to easing discomfort during periods of heightened symptoms.”

---

Primary Therapeutic Benefit: Relief for Acute, Moderate Pain

A key therapeutic benefit is offering additional symptomatic support to help ease the overall burden of acute, localized manifestations that create noticeable functional strain.

Eligibility Map: Who can and cannot use Solpadeine Max (+Caffeine) — official regulatory information

Eligibility Scope

Classification	Populations and Conditions	Restrictions and Caveats
Allowed	Adults; Patients older than 12 years of age.	Use is for the short-term treatment of acute, moderate pain only.
Not Recommended	Adolescents (12–18 years) with compromised respiratory function.	Use requires careful evaluation due to the risk of codeine-related opioid toxicity.
Contraindicated	Children below 12 years of age; Women who are breastfeeding; Patients known to be CYP2D6 ultra-rapid metabolisers; All paediatric patients post-tonsillectomy/adenoidectomy for obstructive sleep apnoea; Patients with significant respiratory depression, acute asthma, or known hypersensitivity to any ingredient.	Prohibitions are due to the potential for severe adverse reactions, including life-threatening respiratory events.

Condition-Specific Eligibility Rules

• Organ Impairment: Eligibility is restricted in patients with severe hepatic impairment or severe renal impairment, requiring medical consideration before use.
• Comorbidities: Use is restricted for patients with certain conditions, including chronic constipation, known or suspected gastrointestinal obstruction, or a history of substance abuse.
• Physiological Status: Use is generally not recommended during pregnancy and is strictly contraindicated during lactation (breastfeeding).

Eligibility Classifications (High-Level)

• Eligibility Severity Classification: Contraindicated (absolute prohibition); Not Recommended (avoidance advised); Use with Caution (requires monitoring).
• Eligibility-Context Constraints: Restrictions are often tied to the patient’s CYP2D6 metabolic status, respiratory function, or post-operative status.

Connection to the overall eligibility profile

The regulatory profile defines who can and cannot use the medicine by establishing clear exclusion criteria, primarily based on age, metabolic capacity, and the status of vital organs. These official constraints, established by governmental authorities, prohibit use in high-risk populations to mitigate the dangers associated with codeine and excessive paracetamol exposure. Eligibility is limited to individuals aged 12 and above who do not present the specific contraindications listed in the regulatory documents.

Interactions with other medicines and products

Official regulatory information for Solpadeine Max (+Caffeine) establishes several restrictions on co-administration, primarily concerning the codeine and acetaminophen components.

Classification	Interacting Substance/Class	Official Constraint
Contraindicated	MAO Inhibitors (Isocarboxazid, Phenelzine, etc.)	Prohibited for concurrent use or use within 14 days of stopping MAOIs.
	Other Acetaminophen Products	Must not be used simultaneously to prevent exceeding the total daily dose and risking hepatic injury.
Pharmacodynamic	CNS Depressants (including alcohol)	Concomitant use may result in profound sedation, respiratory depression, coma, and death.
	Serotonergic Drugs	Concomitant use may lead to Serotonin Syndrome.
Pharmacokinetic	CYP2D6 Inhibitors (e.g., Amiodarone, Quinidine)	May reduce analgesic efficacy by decreasing the formation of the active metabolite, morphine.
Exposure Risk	Sodium Warfarin (Coumarin anticoagulants)	Chronic use of acetaminophen may cause an increase in International Normalized Ratio (INR), requiring monitoring.
	Alcohol (Ethanol)	Increases the risk of severe liver damage from acetaminophen when three or more drinks are consumed daily.

The drug is contraindicated in patients with severe hepatic impairment due to the acetaminophen component. Additionally, the label notes that the interaction with CYP2D6 is critical, as ultra-rapid metabolizers of codeine are also formally contraindicated. Restrictions also extend to Mixed Agonist Opioid Analgesics, which should be avoided as they may reduce the pain-relieving effect or precipitate withdrawal symptoms.

Solpadeine Max (+Caffeine) modulates physiological responses via three distinct pharmacodynamic mechanisms acting across the central and peripheral nervous systems. The codeine component is metabolized to an active molecule that functions as an agonist at G-protein-coupled mu-opioid receptors in the CNS. This binding modifies descending inhibitory pathways and neurotransmitter release, affecting afferent signal processing.

Simultaneously, paracetamol (acetaminophen) is thought to act centrally by inhibiting the synthesis of prostaglandins, which are pivotal signaling molecules involved in heightened physiological processes. This action reduces prostaglandin synthesis, resulting in decreased mediator activity on thermal regulation and sensation pathways.

The final component, caffeine, exerts an antagonistic effect at non-selective adenosine receptors in the CNS. This antagonism modulates key pathways associated with cellular signaling, leading to the suppression of adenosine-mediated signaling and modification of downstream cellular responses in combination with the other components.

How to Use Solpadeine Max (+Caffeine): Official Administration Guidelines

The use of this triple-component analgesic is strictly defined by official instructions that cover dosing limits, frequency, duration, and administration logistics.

---

Dosage and Administration Structure

Usage Parameter	Official Regulatory Instruction
Route of Administration	For oral administration only. Effervescent tablets must be dissolved in at least half a glass of water before consumption.
Standard Single Dose	Adults/Adolescents (≥ 16 years): Two tablets (1000 mg Paracetamol / 25.6 mg Codeine / 60 mg Caffeine).
Dosing Frequency	Doses must not be repeated more frequently than every 4 hours.
Maximum Daily Dose	No more than eight tablets (4000 mg Paracetamol) should be taken within a 24-hour period.
Duration Constraint	Treatment is strictly limited to a maximum of 3 consecutive days.

---

Population and Special Conditions

Use in the pediatric population is subject to specific limits. The medicine is not to be given to children below 12 years of age for analgesic purposes. For adolescents aged 12 to 15 years, the standard dose is one tablet, with a maximum limit of four tablets in 24 hours. The dosing interval for this age group is extended to a minimum of six hours.

Patients with renal impairment may require an increase in the minimum dosing interval to at least six hours, and dose reduction may be necessary in the presence of hepatic impairment. When using the effervescent form, patients on a controlled sodium diet should note that each tablet contains a high amount of sodium.

Research Findings and Study Overview

Research has examined a combination of two drug components (paracetamol/acetaminophen and codeine) and the adjuvant caffeine, investigating their potential relationship to pain relief outcomes in various studies.

Early studies examined the hypothesis that the drug was associated with the body’s pain response. Research explored whether this combination was linked to changes in pain and inflammation scores, with some participants reporting relief.

---

Clinical Study Findings

Clinical trials have primarily focused on the combination's performance in acute pain states, such as dental pain and post-operative pain.

• Codeine Component: The addition of codeine to paracetamol was studied for its potential to provide a small, statistically significant increase in the proportion of participants achieving a good level of pain relief compared to paracetamol alone.
• Caffeine Component: Studies analyzed the inclusion of caffeine (typically 65 mg) and found it may act as an analgesic adjuvant, investigated for its potential to enhance the analgesic effect of paracetamol in certain acute pain settings.

---

Safety and Tolerability Profile

Adverse events were reported at specific rates in the studied participant groups. Common adverse events documented in the research included nausea, vomiting, dizziness, and headache. The combination of codeine and paracetamol introduces specific risks:

• Hepatotoxicity Risk: The potential for liver damage associated with paracetamol remains, particularly with use at high doses or in overdose.
• Opioid Risk: As codeine is converted to morphine in the body, it carries the risks associated with opioids, including the potential for dependence, misuse, and respiratory depression, particularly in certain genetic subgroups (CYP2D6 ultra-rapid metabolizers).

Key Studies & References

1. Codeine and dependence: clinical guidelines

Common questions about Solpadeine Max (+Caffeine) (FAQ)

Q: Is Solpadeine Max addictive?

This medicine contains codeine, an opioid component. Official regulatory documents indicate that codeine carries a risk of developing physical and psychological dependence (often referred to as addiction) and tolerance with regular use, even when taken at therapeutic doses. Regulatory documents limit the duration of use to a maximum of three consecutive days.

Q: What are the common side effects of Solpadeine Max?

According to the official product safety information, common side effects are generally related to the central nervous system and the gastrointestinal system. The most frequently reported effects include nausea, vomiting, dizziness, drowsiness, and constipation.

Q: Can Solpadeine Max be crushed or split to make it easier to swallow?

Regulatory instructions specify that the effervescent form of this medicine must be dissolved in water before being consumed. For the standard compressed tablets, official product information does not generally provide instructions to crush or split them. Regulatory information indicates that administration should align with the method described on the product label. Altering the tablet form may affect how the medicine is absorbed.

Q: How do I know if the medicine is expired?

The expiration date (often labeled as EXP) can typically be found on the medicine's packaging, such as the outer box or the blister strip. Official guidance states that the medicine should not be used after this printed date has passed, as its stability and effectiveness may be compromised.

How to Store and Dispose of Solpadeine Max

The official storage requirements for Solpadeine Max tablets are strictly defined by temperature, environmental conditions, and packaging to maintain product stability.

Requirement	Official Regulatory Statement
Storage Temperature	Store the product below 25 C in a cool, dry place.
Environmental Protection	Keep the medicine in its original package to protect it from light and moisture.
Child Safety	The product must be kept out of the sight and reach of children.
Disposal	Do not dispose of unused or expired medicine via wastewater or household waste. Consult a pharmacist for instructions on proper disposal to protect the environment.

These instructions ensure that the medicine remains effective until its expiry date and is discarded safely according to pharmaceutical waste protocols.